LY3295668 Erbumine clinical trials

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

This study is looking at a new medicine called LY3295668 erbumine for children and young people aged 2 to 21 with a type of cancer called neuroblastoma. We want to find out if this medicine is safe when neuroblastoma has come back or not responded to other treatments.